Skip to main content
. 2022 Aug 24;19:19. doi: 10.1186/s12977-022-00598-0

Fig. 5.

Fig. 5

Analysis of the binding of recombinant gp85 s3 protein point mutants for the Tva receptor. a, b Co-IP test results and grey value analysis results for the interactions between soluble recombinant chimeric gp85 proteins and the Tva receptor; c evaluation of the efficiencies of soluble recombinant chimeric gp85 proteins in competitively blocking RCASBP(A)-EGFP infection. Three independent experiments were performed, and the data are shown as the mean ± SD of triplicate samples from a representative experiment. Statistical analysis (two-way analysis of variance) was performed using GraphPad Prism 7; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001